Background {#Sec1}
==========

Stress ulcer prophylaxis (SUP) is an important concern in intensive care. Some previous studies have reported that 5 to 25% of critically ill patients without SUP develop upper gastrointestinal bleeding (UGIB) due to the severity of illness and/or invasive treatments \[[@CR1], [@CR2]\]. A systematic review and meta-analysis showed that histamine type 2 receptor blockers (H2Bs) and proton pump inhibitors (PPIs) significantly reduced the incidence of UGIB in critically ill adult patients \[[@CR3]\]. Nonetheless, H2Bs and PPIs have been shown to increase the incidence of hospital-acquired pneumonia (HAP) and *Clostridioides difficile* infection (CDI) \[[@CR4]--[@CR6]\].

Currently, medical checklists are widely used to maintain the compliance of medications and interventions in intensive care units. Previous studies have reported that utilizing medical checklists improved the quality of patient care and reduced patient mortality and length of ICU stay \[[@CR7]--[@CR9]\].

However, the efficacy of medical checklists in terms of reducing the UGIB incidence and unnecessary administration of SUP medications has not been sufficiently explored yet.

This study aimed to investigate the incidence of UGIB and rate of administering SUP medications before and after setting administration criteria for SUP and introducing a medical checklist in critically ill adults.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

This was a retrospective pre-post intervention, noninferiority study conducted at a single-center, tertiary adult and pediatric mixed ICU. Institutional ethical committee approval was obtained (approval number 60-19-0014). In this study, we analyzed patients admitted to the ICU between September 2014 and April 2015. At our ICU, we used a routine set of orders that included maintenance fluid and H2B together to recall the administration of H2B as a SUP that potentially resulted in the unnecessary administration of H2B as SUP in the preintervention period. If there was a contraindication for H2B, we administered PPI instead of H2B.

Intervention {#Sec4}
------------

The interventions comprised the following three actions: introduction of a medical checklist (Table [1](#Tab1){ref-type="table"}), removal of H2B from the routine set of orders that included maintenance fluid and H2B together, and creating SUP criteria (Table [2](#Tab2){ref-type="table"}). These interventions were introduced on December 22, 2014. Prior to introducing these interventions, all the ICU medical professionals were instructed about the medical checklist and SUP criteria through department conferences and didactic lectures. The SUP criteria were created based on the reported criteria in previous reports \[[@CR11]--[@CR13]\]. Table 1Checklist used in the ICUContentsAssessmentAnalgesia□Good □BadSedation□Good □BadDelirium□Yes □No □Cannot evaluate (RASS, − 4 to − 5)Medical restraint□Applied □Necessary □Not necessaryMechanical ventilation Spontaneous mode or SBT□Applied □Possible □Impossible Airway extubation□Possible □ImpossibleHead elevation at least 30°□Yes □No □Impossible □ProhibitedRehabilitation□Yes □No □Not applicableDeep vein thrombosis□Yes □Suspicious □NoAnticoagulants□Applied □Necessary □Not necessaryInotropic agents□Can be reduced □Cannot be reduced □No inotropic agentAdministered caloriesXX kcal/kg/dayRoute of nutrition□Enteral □Total parenteral □ParenteralStress ulcer prophylaxis□Applied □Necessary □Not necessaryLast defecationXX days agoBlood glucose level□Good □BadCorrection of serum electrolyte□Applied □Necessary □Not necessaryDiscontinuance of antibiotics□Possible □Impossible □No antibacterial agentUnnecessary vascular catheter□Yes, now extract □NoUnnecessary urinary catheter□Yes, now extract □NoToday's goal(ex) SBT and airway extubation*RASS* Richmond Agitation Sedation Scale, *SBT* spontaneous breathing trial Table 2SUP criteria used in the ICUMajor adaptation criteria, at least one of the following Coagulopathy (platelets \< 50 × 10^3^/mm^3^ and/or APTT \< 50% and/or PT-INR ≥ 1.5) Mechanical ventilation for more than 48 h A history of UGIB within 1 year Glasgow Coma Scale ≤ 10 Thermal injuries to \> 35% of their body surface area Post partial hepatectomy Multiple trauma (Injury Severity Score ≥ 16) \[[@CR10]\] Transplantation patients Hepatic failure Spinal cord injuryMinor adaptation criteria, at least two of the following Sepsis ICU stay for more than 7 days Occult bleeding lasting 6 days or more Corticosteroids (\> 250 mg/day of hydrocortisone or the equivalent)Exclusion criteria: SUP is not required if one of the following Enteral nutrition has been already administered Early exit from the ICU is expected*APTT* activity of activated partial thromboplastin time, *PT-INR* prothrombin time international normalized ratio

Every morning, the medical checklist was reviewed by the ICU physicians and nurses to share the treatment policy and to not forget necessary routine medical practices, such as the SUP. If necessary, the protocols or criteria for the checklist item were referenced (for example, sedation protocol, enteral nutrition protocol, and SUP criteria), and the ICU physicians made a clinical decision about those. Patients who had one of the major adaptation criteria or at least two of the minor adaptation criteria (Table [2](#Tab2){ref-type="table"}) were administered SUP medications if they did not have any exclusion criteria. However, some patients who were considered to be at a higher risk for UGIB could be administered SUP medications at the direction of the ICU attending physician even if they were included in the SUP exclusion criteria.

Pre- and postinterventional groups {#Sec5}
----------------------------------

Adult patients (≥ 18 years) admitted to the ICU were classified into the preintervention group (from September to December 21, 2014) and the postintervention group (from December 22, 2014, to April 2015). Readmission to the ICU within 48 h was considered to be consecutive for ICU management. Patients admitted to the ICU for gastrectomy, esophagectomy, pancreatoduodenectomy, and gastrointestinal bleeding were excluded. Patients who did not receive SUP although they were admitted to the ICU in the preintervention period were excluded. As for the postintervention group, patients who received SUP although they did not meet the SUP major or minor criteria were excluded. Patient data before and after the interventional day were collected until the required sample size was fulfilled.

Outcomes and patient demographics {#Sec6}
---------------------------------

The primary outcome was the incidence of UGIB defined as one of the following two conditions. First, an ICU physician made a diagnosis of UGIB based on the findings of incessant bloody drainage through a nasogastric tube (NGT) and/or melena. Second, anemia proceeded (the hemoglobin level decreased more than 1 g/dL) within 2 days after there were intermittent signs of bloody drainage through a NGT and/or melena. The NGTs were kept open. The nurses checked the character of the drainage by suctioning the NGTs every 2 to 4 h when administering nutrition and/or medications. The secondary outcome was the proportion of administered SUP medications and the incidence of HAP and CDI. SUP was defined as intravenous or oral H2Bs and/or PPIs. These drugs were considered to be administered if they were administered even once. For example, in a case that we discontinued SUP for some patients on SUP (in case enteral nutrition was started for patients with SUP), these patients were considered to have received a SUP if they were administered a SUP even once. If SUP drugs were changed (from H2B or PPI to another) for any reasons during the ICU stay, both drugs were considered to be administered. HAP was defined if antibiotics were administered against suspected pneumonia at more than 48 h after hospitalization. The definition for CDI included the following findings: presence of diarrhea, positive stool culture result, and positive finding in enzyme immunoassay testing for *Clostridioides difficile* toxin A or B \[[@CR14]\].

We also investigated clinically significant UGIB (CSUGIB), which is defined as a UGIB that made patients require at least one of the following: red blood cell transfusion, surgical or endoscopic treatments, and vasopressor agents due to aggravation of the vital signs.

The following patient characteristics were recorded: age, sex, Acute Physiology and Chronic Health Evaluation (APACHE) II score \[[@CR15]\], Sequential Organ Failure Assessment (SOFA) score \[[@CR16]\] at entry, Glasgow Coma Scale (max score or the ICU exit day's score if the patient had new central nervous system disorder during ICU stay), length of stay in the ICU, 30-day mortality, admission classification (postoperative or internal, cardiovascular or other surgery), operation time for postoperative patients, UGIB history within 1 year, sepsis (2 points or more increase in SOFA score due to infection \[[@CR17]\]), septic shock (sepsis and serum lactate level \> 2 mmol/L and necessity of volume resuscitation and vasopressor agents \[[@CR17]\]), hepatectomy, hepatic failure (prothrombin time international normalized ratio (PT-INR) ≥ 1.5 resulting from acute liver injury, and/or Child-Pugh classification C cirrhosis), multiple trauma (Injury Severity Score \[[@CR10]\] ≥ 16), coagulopathy (platelets \< 50 × 10^3^/mm^3^ and/or activity of activated partial thromboplastin time (APTT) \< 50% and/or PT-INR ≥ 1.5), thermal injuries (\> 35% of their body surface area), organ transplantation, spinal cord injury, duration of mechanical ventilation, blood purification therapy (chronic or intermittent renal replacement therapy and/or plasma exchange), percutaneous cardiopulmonary support, enteral feeding, administration of corticosteroids (\> 250 mg/day of hydrocortisone or equivalent), aspirin, warfarin, heparin, and other anticoagulants and/or antiplatelet drugs.

Statistical analysis {#Sec7}
--------------------

The chi-squared test was utilized to compare the proportions of categorical variables, and the Mann-Whitney *U* test was applied to compare the continuous variables and ordinal variables. The test results for continuous and ordinal variables are reported as the median and interquartile range (IQR) based on the normality of data distribution. All statistical analyses were performed using EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria, version 3. 3. 1) \[[@CR18]\]. For the noninferiority test, one-tailed test was applied while two-tailed tests were performed for other tests. *p* values \< 0.05 were considered statistically significant.

Sample size calculation {#Sec8}
-----------------------

Previous studies reported that the incidence of UGIB without SUP in critically ill adults was 5 to 25% \[[@CR1]--[@CR3]\]. From the average value of 15%, it was considered that there was a change range of 10%; therefore, in this study, the noninferiority margin was set at 10%. We received advice from our statistical experts regarding this point. In a preliminary survey at our ICU, we found that the incidence of UGIB in critically ill adults was 4%. If the primary outcome of the preintervention and postintervention groups was 4%, the calculated sample size of every group was 48 (*α* = 0.05, power = 0.8, one-sided test).

Results {#Sec9}
=======

In total, 100 patients in the pre- (*n* = 50) and postintervention (*n* = 50) groups were analyzed. No patient was classified in duplicate into the pre- and postintervention groups. NGTs were placed in all patients to administer enteral nutrition and medications. As shown in Fig. [1](#Fig1){ref-type="fig"}, in the preintervention group, all patients received SUP and 2 patients had UGIB. In the postintervention group, 36 patients were classified into the major or minor SUP criteria. Seventeen of them did not receive SUP because they were included in the SUP exclusion criteria: 10 patients received enteral nutrition and 7 patients were discharged from the ICU after 2 days. Of the 36 patients who were classified into the major or minor SUP criteria, 19 received SUP, 8 started to receive enteral nutrition after the administration of SUP medications, and 1 of the remaining 11 patients who received SUP without enteral nutrition had UGIB. Moreover, one of the patients who were not administered SUP medications because they were already started with enteral nutrition had CSUGIB. Fig. 1Flowchart of pre- and postintervention groups. SUP, stress ulcer prophylaxis; UGIB, upper gastrointestinal bleeding; CSUGIB, clinically significant UGIB

Patient demographics {#Sec10}
--------------------

No significant differences were found in the patient demographics between the pre- and postintervention groups (Table [3](#Tab3){ref-type="table"}). Table 3Patient demographicsPreintervention, *n* = 50Postintervention, *n* = 50*p*Age, years, median (IQR)67 (60--75)71 (60--77)0.54Sex, male, *n* (%)33 (66)25 (50)0.16APACHE II score, median (IQR)15 (10--18)17 (10--23)0.16SOFA score at entry, median (IQR)4 (2--6)5 (2--8)0.46Glasgow Coma Scale ≤ 10, *n* (%)6 (12)8 (16)0.77Length of stay in ICU, days, median (IQR)3 (2--6)3 (2--9)0.41ICU stay for more than 7 days, *n* (%)12 (24)17 (34)0.3830-day mortality, *n* (%)7 (14)4 (8)0.52Classification Postoperative, cardiovascular, *n* (%)2 (4)2 (4)1.00 Postoperative, others, *n* (%)32 (64)25 (50)0.23 Internal, *n* (%)16 (32)23 (46)0.22Operation time, min, median (IQR)449 (198--668)435 (165--599)0.59UGIB history within 1 year, *n* (%)1 (2)4 (8)0.36Sepsis, *n* (%)18 (36)28 (56)0.07Septic shock, *n* (%)6 (12)11 (22)0.29Hepatectomy, *n* (%)1 (2)3 (6)0.61Hepatic failure, *n* (%)1 (2)3 (6)0.61Multiple trauma, *n* (%)0 (0)2 (4)0.48Coagulopathy, *n* (%)20 (40)29 (58)0.11Mechanical ventilation, hours, median (IQR)10 (0--59)18 (3--123)0.13Mechanical ventilation for more than 48 h, *n* (%)14 (28)19 (38)0.40Blood purification therapy, *n* (%)3 (6)9 (18)0.12Enteral feeding, *n* (%)17 (34)21 (42)0.54Steroid, *n* (%)5 (10)8 (16)0.55Aspirin, *n* (%)3 (6)3 (6)1.00Warfarin, *n* (%)2 (4)2 (4)1.00Heparin, *n* (%)8 (16)14 (28)0.23Other anticoagulants or antiplatelets, *n* (%)5 (10)11 (22)0.17Other anticoagulants or antiplatelet drugs contained low-molecular-weight heparin, danaparoid sodium, nafamostat mesylate, direct thrombin inhibitor, ozagrel sodium, clopidogrel sulfate, and cilostazol*IQR* interquartile range, *APACHE II* Acute Physiology and Chronic Health Evaluation II, *SOFA* Sequential Organ Failure Assessment, *UGIB* upper gastrointestinal bleeding

Incidence of UGIB {#Sec11}
-----------------

No significant difference was found regarding the incidence of UGIB between the groups (Table [4](#Tab4){ref-type="table"}). As previously described, the noninferiority margin for the incidence of UGIB was 10%. The upper limit of 95% confidence interval (CI) of the incidence of UGIB for the postintervention group (13.7%) was lower than the predefined line (4% + 10% = 14%) (Fig. [2](#Fig2){ref-type="fig"}). Additionally, no significant difference was found regarding CSUGIB (Table [4](#Tab4){ref-type="table"}). Table 4Incidence of UGIB and CSUGIBPreintervention, *n* = 50Postintervention, *n* = 50*p*UGIB, *n*, % (95% CI)2, 4% (0.5--13.7%)2, 4% (0.5--13.7%)1.00CSUGIB, *n* (%)0 (0)1 (2)1.00*UGIB* upper gastrointestinal bleeding, *CSUGIB* clinically significant UGIB, *CI* confidence interval Fig. 2The incidence of UGIB in pre- and postintervention groups. That of preintervention group was 4%. The noninferiority margin was set at 10%; therefore, 4% + 10% = 14% was the predefined line. The incidence of UGIB in postintervention group was 4% \[95% CI, 0.5--13.7%\]. This upper limit of 95% CI (13.7%) was lower than the predefined line (14%).UGIB, upper gastrointestinal bleeding; CI, confidence interval

Proportion of patients administered with SUP and incidence of HAP and CDI {#Sec12}
-------------------------------------------------------------------------

The proportion of the patients who received a SUP was significantly decreased in the postintervention group compared with that in the preintervention group (Table [5](#Tab5){ref-type="table"}). In preintervention group, PPI was administered to some patients instead of H2B due to renal failure. Additionally, SUP drugs were changed from H2B to PPI in some patients when renal failure was newly diagnosed during their ICU stay. In these cases, the patients in the preintervention group were considered to be administered both H2B and PPI. No significant difference was found regarding the incidence of HAP and CDI (Table [5](#Tab5){ref-type="table"}). Table 5Proportion of the patients who received SUP and incidence of HAP and CDIPreintervention, *n* = 50Postintervention, *n* = 50*p*SUP, *n* (%)50 (100)19 (38)\<0.001H2B, *n* (%)42\* (84\*)7 (14)PPI, *n* (%)15\* (30\*)12 (24)HAP, *n* (%)7 (14)3 (6)0.32CDI, *n* (%)0 (0)0 (0)1.00*SUP* stress ulcer prophylaxis, *H2B* histamine type 2 receptor blocker, *PPI* proton pump inhibitor, *HAP* hospital-acquired pneumonia, *CDI Clostridioides difficile* infection\*Some patients in the preintervention group were administered both H2B and PPI; thus, the total was greater than 100%

Discussion {#Sec13}
==========

To our knowledge, this is the first study to examine whether UGIB increased if SUP was reduced from all to limited cases using a checklist and SUP criteria in the intensive care. Our study showed that the applied interventions could reduce administration of unnecessary SUP and did not increase the incidence of UGIB in critically ill adults, which might have occurred because the SUP criteria facilitated the selection of a high-risk population with stress ulcers, and we did not forget to administer a SUP because of the checklist.

Previous reports on checklists have shown that checklists facilitate ICU medical professionals to administer SUP appropriately and improve compliance. However, no study has reported the benefits of using a medical checklist on the incidence of UGIB with the reduction of unnecessary SUP.

Appropriate selection of a high-risk patient population with stress ulcers is vital to maximize the benefits of SUP with minimum adverse effects. Although it is reasonable that not all patients in the ICU need to receive a SUP, no consensus exists concerning modern intensive care. Presently, a randomized controlled trial comparing a SUP and placebo cannot be carried out due to ethical reasons. Thus, our research can give more insight into this topic. However, it should be noted that one patient, for whom we decided a SUP was unnecessary because enteral nutrition was already started, had CSUGIB. CSUGIB was reported to be associated with higher mortality \[[@CR19]\]; therefore, we must reevaluate our work. However, it is unclear whether administration of a SUP to that patient could have prevented UGIB \[[@CR20]\]. Moreover, the incidence of CSUGIB was too low to investigate; therefore, further investigations are needed. In detail, although this patient was admitted to the ICU owing to heart and respiratory failure, he had undergone distal gastrectomy two months before this admission. When he entered the ICU, the surgical wound in the digestive tract was thought to have been healed and enteral nutrition was started. However, bloody drainage through the NGT and melena were found; therefore, enteral nutrition was stopped and PPI was administered. Blood transfusions were performed to treat anemia. His condition was improved, and he was discharged from the ICU after 2 weeks.

There were four patients who had UGIB (as shown previously, one of them had CSUGIB) in this study (Fig. [1](#Fig1){ref-type="fig"}). One of them in the preintervention group was a patient with septic shock during treatment of hematological malignancy. He had multiple major and minor risk factors for UGIB (coagulopathy, mechanical ventilation for more than 48 h, Glasgow Coma Scale ≤ 10, sepsis, and ICU stay for more than 7 days) (Table [2](#Tab2){ref-type="table"}). Although he was administered both a SUP medication and enteral nutrition, he had UGIB. The cause of UGIB is unknown because gastrointestinal endoscopy was not performed. He died of multiple organ failure associated with septic shock 22 days after entering the ICU. Another patient with UGIB in the preintervention group was admitted to the ICU after an endovascular aneurysm repair for rupture of abdominal aortic aneurysm. Though he also received SUP, he had UGIB. During the endovascular treatment, the radiologist had concerns about transient intestinal ischemia, which was considered to be the cause of UGIB. The patient did not receive enteral nutrition. His condition was improved in 3 days, and he was discharged from the ICU. A patient with UGIB (not CSUGIB) in the postintervention group was admitted to the ICU owing to edema of the airway associated with systemic capillary leak syndrome. She had received SUP, while enteral nutrition had not been started. She fell in cardiopulmonary arrest in the ICU owing to airway obstruction caused by rapid airway edema. After 11 min of cardiopulmonary resuscitation, she was resuscitated. On the day after the resuscitation, bloody drainage in the NGT was found. The cause was thought to be ischemia of the gastrointestinal mucosa owing to cardiopulmonary arrest. Her brain was seriously damaged by cardiopulmonary arrest. A tracheotomy was applied, and she was moved to the general ward while continuing to receive SUP.

This type of intervention might decrease medical costs \[[@CR21]\]. Moreover, less opportunity for SUP medication should have resulted reductions of adverse effects, risk of medical errors, and time and effort of nurses. On the other hand, only a few minutes per patient during the morning round would be needed. The incidence of UGIB, length of stay in ICU, and 30-day mortality were not increased; therefore, the total cost of medical care would also not be increased. Therefore, the concept of this intervention can be adapted to any facility.

It was already mentioned that these intervention methods will help us to homogenize the quality of medical care, allowing us to maintain the quality of medical care regardless of facility and staff. Importantly, the methods should be simple and easy to execute, leading to reliability and validity. Additionally, the methods may increase medical professionals' knowledge about UGIB and SUP. For example, although a computing system that automatically determines the need for a SUP may be useful to homogenize the quality of medical care, it will not increase our knowledge about SUP. It is important for medical professionals to have updated knowledge about SUP.

No significant differences were found in the length of stay in the ICU and 30-day mortality. First, a previous study reported that administration of a SUP in critically ill adults did not improve all-cause mortality \[[@CR3]\]. H2Bs and PPIs as SUP have advantages and disadvantages: a decrease in the incidence of UGIB but an increase in HAP and CDI. Although no significant differences were found in the incidence of HAP and CDI, this study was not designed to detect these events. In theory, the risk of these side effects is considered to be reduced because we stopped unnecessary medication. Further research on a larger sample size is needed.

About 4 years have passed since the end of the data collection period, but our checklist and SUP criteria are still in use. The proportion of administered SUP is about 40% now. However, even after the start of enteral nutrition, there seems to be a tendency to continue SUP for patients with higher risk for UGIB.

This study possessed several limitations. First, the reported incidence of UGIB included a wide variation in the results, and the standard treatments in intensive care units may have changed over the past few decades. The quality of intensive care has steadily improved; therefore, the real incidence of UGIB might be lower than we expected. Second, this was a retrospective study; therefore, it was not necessary to detect all UGIB cases precisely. Third, all of the possible confounders were not collected. Fourth, an issue of misclassification may exist in this study. Although we discontinued SUP for some patients with SUP (for example, if enteral nutrition was started for patients with SUP), these patients were considered to have received a SUP if they were administered a SUP even once. Finally, the before and after study may have not captured other modifications in practice over the observed time period. The short timeline (8 months) reduces the risk that some undetected factor changed during the period. We have not evaluated the reliability and validity of the checklist and SUP criteria. Generalization to different facilities and patient populations has not been investigated.

Conclusions {#Sec14}
===========

Utilizing a checklist and SUP criteria reduced unnecessary administration of SUP medications. Regarding the incidence of UGIB in critically ill adults, no significant difference was found between the group that was administered SUP medications on a daily basis and the group restricted to being administered a SUP medication utilizing a checklist and the SUP criteria. In future research, a prospective controlled trial needs to be conducted to evaluate the impact of the proposed method on reducing both the unnecessary usage of SUP medicines and gastrointestinal bleeding.
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